- OraSure (OSUR +16.1%) is among the day's big winners after the company reported a Q2 loss that was narrower than analysts expected.
- Revenue growth of 8% for the period was attributable to strong sales of OSUR's "molecular collection systems and infectious disease testing products."
- OSUR guided for a Q3 net loss of $0.09-0.10/ share versus Street estimates of a $0.12 loss. Revenue guidance is in line with consensus. (PR)
From other sites
Video at CNBC.com (May 19, 2015)
at CNBC.com (Nov 19, 2012)
at CNBC.com (Oct 23, 2012)
at CNBC.com (Oct 8, 2012)
at CNBC.com (Jul 13, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs